Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Non-Insulin Therapies For Diabetes Market In 2029?
The market for non-insulin diabetes treatments has seen robust growth recently. Forecasted to rise from $19.98 billion in 2024 to $21.21 billion in 2025, it’s expected to have a compound annual growth rate (CAGR) of 6.1%. The past growth can be credited to numerous reasons including growing incidents of diabetes, heightened awareness about managing the condition, an increase in healthcare spending, lifestyle changes resulting in increased occurrence, a surge in diagnosis, greater governmental initiatives for diabetes treatment, as well as increased pharmaceutical R&D investments.
In the upcoming years, the market for non-insulin treatments for diabetes is anticipated to experience robust growth, escalating to a value of $26.98 billion in 2029 with a CAGR of 6.2%. This growth during the projected period can be credited to factors such as the escalating prevalence of diabetes, heightened awareness of diabetes control, widespread adoption of combination therapies, the expanding aging population, increased expenditure on healthcare, growth of telemedicine, and a growing preference for orally administered medications. Key trends throughout this forecast period encompass developments in oral and injectable drugs, progress in drug delivery systems, improvement in oral peptide delivery, the rise of telemedicine and digital health solutions, and advancements in combination therapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16494&type=smp
What External and Internal Drivers Are Contributing to the Growth of theNon-Insulin Therapies For Diabetes Market?
The escalating occurrence of diabetes is projected to boost the expansion of non-insulin treatments in the diabetes market. Diabetes is a long-term health problem characterized by elevated glucose (sugar) levels in the blood. This condition happens when the body is unable to produce sufficient amounts of insulin or use insulin effectively. Lifestyles lacking in physical activity, unhealthy diets, inherited factors, aging populations, obesity, ethnic differences, unawareness, inadequate healthcare access, and environmental conditions all contribute to the rising number of diabetes cases. Non-insulin diabetes treatments aid in managing the disease by increasing insulin sensitivity, decreasing glucose production in the liver, augmenting glucose uptake in muscle cells, and optimizing overall glycemic regulation. For example, a report by The British Diabetic Association, a diabetes charity based in the UK, stated in April 2023 that 4.3 million individuals in the UK were diagnosed with diabetes. Enrollment data from 2021-22 indicated a surge of 148,951 cases compared to the previous year. Furthermore, over 2.4 million individuals in the UK have a high chance of developing type 2 diabetes. Consequently, the escalating occurrence of diabetes is propelling the growth of non-insulin treatments in the diabetes market.
What Segment Types Define the Non-Insulin Therapies For Diabetes Market Structure?
The non-insulin therapies for diabetesmarket covered in this report is segmented –
1) By Drug Class: Biguanides; Sulfonylureas; Thiazolidinedione’s; Alpha-Glucosidase Inhibitors; Dipeptidyl peptidase-4 (DPP-4) Inhibitors; Glucagon-like peptide-1 (GLP-1) Analogs; Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral; Intramuscular
3) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
4) By Application: Monitoring; Diagnosis; Treatment; Other Applications
Subsegments:
1) By Biguanides: Metformin; Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride; Glipizide; Glyburide
3) By Thiazolidinediones: Pioglitazone; Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide; Liraglutide; Dulaglutide; Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=16494&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Non-Insulin Therapies For Diabetes Market?
North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Long-Term Trends Are Transforming the Competitive Landscape of the Non-Insulin Therapies For Diabetes Market?
Major players in the non-insulin diabetes treatment market are focusing on creating personalized diabetes management systems. These systems aim to improve patient results by utilizing live monitoring, data analysis, and tailored treatment plans. The personalized diabetes management system adjusts treatment and supervision according to the unique requirements of each patient, utilizing live data and analytics to improve care and performance. For instance, in November 2022, Eli Lilly and Company, a pharmaceutical company based in the United States, introduced the Tempo personalized diabetes management platform. The Tempo platform comprises three key features—the Tempo Smart Button, the TempoSmart app, and the prefilled insulin pen, the Tempo Pen. These elements work together to offer customized advice for adults diagnosed with diabetes. The platform is created to help adults suffering from type 1 or type 2 diabetes and their healthcare providers in making knowledgeable, data-backed treatment decisions using Lilly insulins.
View the full report here:
What Is the Definition of the Non-Insulin Therapies For Diabetes Market?
Non-insulin therapies for diabetes refer to medications and treatments used to manage blood sugar levels in diabetic patients without the use of insulin injections. They are essential for regulating blood sugar levels in patients, who either do not need or prefer insulin injections.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16494
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model